Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo‐controlled crossover study

Background : Dopamine D2 receptor antagonists used to treat Tourette syndrome may have inadequate responses or intolerable side effects. We present results of a 4‐week randomized, double‐blind, placebo‐controlled crossover study evaluating the safety, tolerability, and efficacy of the D1 receptor antagonist ecopipam in children and adolescents with Tourette syndrome. Methods : Forty youth aged 7 to 17 years with Tourette syndrome and a Yale...